Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Thambisetty, Madhava; 1; * | Tripaldi, Rominab; 1 | Riddoch-Contreras, Joannab; 1 | Hye, Abdulb | An, Yanga | Campbell, Jamesc | Sojkova, Jitkaa | Kinsey, Annab | Lynham, Stevenb | Zhou, Yund | Ferrucci, Luigie | Wong, Dean F.d | Lovestone, Simonb; 1 | Resnick, Susan M.a; 1
Affiliations: [a] National Institute on Aging, Baltimore, MD, USA | [b] Institute of Psychiatry, London, UK | [c] Proteome Sciences plc, London, UK | [d] Department of Radiology, Johns Hopkins University, Baltimore, MD, USA | [e] Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, MD, USA
Correspondence: [*] Correspondence to: Madhav Thambisetty, MD, PhD, Room 4B-311, 251 Bayview Blvd, National Institute on Aging (NIA), National Institutes of Health (NIH), Baltimore, MD 21224, USA. Tel.: +1 410 558 8572; Fax: +1 410 558 8674; E-mail: thambisettym@mail.nih.gov.
Note: [1] These authors contributed equally to the manuscript.
Abstract: Blood-based markers reflecting core pathological features of Alzheimer's disease (AD) in pre-symptomatic individuals are likely to accelerate the development of disease-modifying treatments. Our aim was to discover plasma proteins associated with brain amyloid-β (Aβ) burden in non-demented older individuals. We performed discovery-phase experiments using two dimensional gel electrophoresis (2DGE) and mass spectrometry-based proteomic analysis of plasma in combination with 11C-PiB PET imaging of the brain in samples collected 10 years prior to the PET scans. Confirmatory studies used ELISA assays in a separate set of blood samples obtained within a year of the PET scans. We observed that a panel of 18 2DGE plasma protein spots effectively discriminated between individuals with high and low brain Aβ. Mass spectrometry identified these proteins, many of which have established roles in Aβ clearance, including a strong signal from apolipoprotein-E (ApoE). In validation-phase studies, we observed a strong association between plasma ApoE concentration and Aβ burden in the medial temporal lobe. Targeted voxel-based analysis localized this association to the hippocampus and entorhinal cortex. APOE ε4 carriers also showed greater Aβ levels in several brain regions relative to ε4 non-carriers. These results suggest that both peripheral concentration of ApoE protein and APOE genotype are related to early neuropathological changes in brain regions vulnerable to AD pathology even in the non-demented elderly. Our strategy combining proteomics with in vivo brain amyloid imaging holds promise for the discovery of biologically relevant peripheral markers in those at risk for AD.
Keywords: Alzheimer's disease, amyloid-β, biomarker, brain, plasma, proteomics
DOI: 10.3233/JAD-2010-101350
Journal: Journal of Alzheimer's Disease, vol. 22, no. 4, pp. 1099-1109, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl